Abstract
Vaccination has contributed significantly to improving public health by reducing the mortality caused by a number of infectious diseases. Thanks to extensive childhood vaccination programs during the past century, the incidences of diseases such as smallpox, diphtheria, tetanus, polio, mumps, rubella, measles, meningitis, and pneumococcus have decreased dramatically. However, infectious diseases are still the major cause of death worldwide, and these cannot be prevented by vaccines yet due to a number of factors such as incomplete vaccine coverage, antigenic drift/shift, and lack of efficient vaccines, which call for continued progress in the field towards development of novel vaccines. The first vaccines used were live, attenuated, or inactivated whole organism vaccines. Due to safety reasons, new generation vaccines are usually of the subunit vaccine type, which are based on highly purified recombinant antigens. The downside of the improved safety is reduced immunogenicity, as compared to the whole organisms, requiring the use of adjuvants to stimulate sufficient immunity. Adjuvants are often particulate in nature and may contain pathogen-associated molecular patterns (PAMPs) that stimulate the immune system via pattern-recognition receptors (PRRs). Subunit vaccines thus constitute highly complex formulations, which require extensive pharmaceutical analysis and quality control to ensure optimal safety, efficacy, and stability. This chapter provides an introduction to vaccinology and the classification of vaccines, which will provide the basis for understanding new approaches and technologies to deliver and formulate human vaccines including the use of new adjuvants and alternative administration routes, which are presented throughout this book.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Awate S, Babiuk LA, Mutwiri G (2013) Mechanisms of action of adjuvants. Front Immunol 4:114
Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, Di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 4:e4384
Bins AD, Van Den Berg JH, Oosterhuis K, Haanen JB (2013) Recent advances towards the clinical application of DNA vaccines. Neth J Med 71:109–117
Bloom DE, Canning D, Weston M (2005) The value of vaccination. World Economics 6:15
Bovier PA (2008) Recent advances with a virosomal hepatitis A vaccine. Expert Opin Biol Ther 8:1177–1185
Casella CR, Mitchell TC (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65:3231–3240
Clem AS (2011) Fundamentals of vaccine immunology. J Glob Infect Dis 3:73–78
Clements CJ, Griffiths E (2002) The global impact of vaccines containing aluminium adjuvants. Vaccine 20(Suppl 3):S24–S33
De Bruijn IA, Nauta J, Gerez L, Palache AM (2006) The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects). Vaccine 24:6629–6631
Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW (2010) Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 16:3149–3157
Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178–196
Ehreth J (2003) The global value of vaccination. Vaccine 21:596–600
Foged C (2011) Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv 2:1057–1077
Galli G, Hancock K, Hoschler K, Devos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I (2009a) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 106:7962–7967
Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, Castellino F (2009b) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 106:3877–3882
Garcon N (2010) Preclinical development of AS04. Methods Mol Biol 626:15–27
Garcon N, Chomez P, Van Mechelen M (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6:723–739
Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N (2010) Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 64:432–438
Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76:141–165
Glenny AT, Pope CG, Waddington H, Wallace U (1926) Immunological notes. XVII–XXIV. J Pathol Bacteriol 29:31–40
Gluck R, Metcalfe IC (2002) New technology platforms in the development of vaccines for the future. Vaccine 20(Suppl 5):B10–B16
Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5:505–517
Huang DB, Wu JJ, Tyring SK (2004) A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect 49:179–209
Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135–145
Mortellaro A, Ricciardi-Castagnoli P (2011) From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease. Immunol Cell Biol 89:332–339
O’Hagan DT, De Gregorio E (2009) The path to a successful vaccine adjuvant—‘the long and winding road’. Drug Discov Today 14:541–551
O’Hagan DT, Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2:727–735
O’Hagan DT (2001) Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 1:273–286
Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19:2673–2680
Rappuoli R (2007) Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25:1361–1366
Ravanfar P, Satyaprakash A, Creed R, Mendoza N (2009) Existing antiviral vaccines. Dermatol Ther 22:110–128
Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23–32
Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19:1597–1608
Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 18:21–25
Robinson HL, Amara RR (2005) T cell vaccines for microbial infections. Nat Med 11:S25–S32
Rodriguez PC, Rodriguez G, Gonzalez G, Lage A (2010) Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 12:17–23
Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM (2010) Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28:1740–1745
Romanowski B, De Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A (2009) Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374:1975–1985
Schiller JT, Castellsague X, Villa LL, Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl 10):K53–K61
Schultze V, D’agosto V, Wack A, Novicki D, Zorn J, Hennig R (2008) Safety of MF59 adjuvant. Vaccine 26:3209–3222
Schwarz TF (2009) Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 26:983–998
Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2:e23803
Walker WT, Faust SN (2010) Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines 9:1385–1398
Wellington K, Goa KL (2003) Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 63:2107–2126
WHO (2004) BCG vaccine. WHO position paper. Wkly Epidemiol Rec 79:27–38
WHO (2012) Summary of WHO position papers—recommendation for routine immunization in: immunization, vaccines and biologicals. World Health Organization, Geneva
WHO Fact Sheet 104. (2012). http://www.who.int/mediacentre/factsheets/fs104/en/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kallerup, R.S., Foged, C. (2015). Classification of Vaccines. In: Foged, C., Rades, T., Perrie, Y., Hook, S. (eds) Subunit Vaccine Delivery. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1417-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1417-3_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1416-6
Online ISBN: 978-1-4939-1417-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)